DRREDDY's weekly performance was modest, with a 0.61% return, outperforming SUNPHARMA but underperforming HINDUNILVR and DIVISLAB. The stock's volatility was relatively moderate at 22.11%, lower than its peers DIVISLAB and SUNPHARMA. The Sharpe Ratio of 0.09 indicates a relatively low risk-adjusted return. Overall, DRREDDY's performance was stable, but not exceptional, and its risk profile was relatively manageable.

[Volatility: 22.11%]